emtricitabine/tenofovir alafenamide (Descovy®)

Reference No. 2771

Publication date:

05/10/2016

Appraisal information

emtricitabine/tenofovir alafenamide (Descovy®) 200 mg/10 mg film-coated tablet
emtricitabine/tenofovir alafenamide (Descovy®) 200 mg/25 mg film-coated tablet

Company:	Gilead Sciences Ltd
BNF category:	Infections
NMG meeting date:	20/07/2016
AWMSG meeting date:	21/09/2016

Submission Type:	Limited Submission
Status:	Recommended
Advice No:	2716
Ratification by Welsh Government:	04/10/2016

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ratification by
Welsh Government

AWMSG advice

Emtricitabine/tenofovir alafenamide (Descovy®) is recommended as an option for use within NHS Wales in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV 1).

Final Appraisal Recommendation (FAR)

Download

Emtricitabine_tenofovir alafenamide (Descovy) 2771 FAR

AWMSG Secretariat Appraisal Report (ASAR)

Download

Emtricitabine_tenofovir alafenamide (Descovy) 2771 ASAR

Clinical Expert (CE) Summary

Download

Emtricitabine_ tenofovir alafenamide (Descovy) 2771 CE summary